Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Future of Sanitation: Strategies for COVID 2.0 and Beyond

COVID-19 – remember when that was still a thing? Everyone thought for sure they’d be saying that by now. But, with daily cases in the U.S. reaching all-time highs and a vaccine rollout that will take much longer than desired, getting things back to a semblance of normalcy isn’t happening anytime soon. And what…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
The Future of Sanitation: Strategies for COVID 2.0 and Beyond

Get featured

Want MarketScale to feature Healthcare?

Book a 15-minute demo and we'll map your Healthcare expertise to the content buyers are searching for.

Book a demo

COVID-19 – remember when that was still a thing? Everyone thought for sure they’d be saying that by now. But, with daily cases in the U.S. reaching all-time highs and a vaccine rollout that will take much longer than desired, getting things back to a semblance of normalcy isn’t happening anytime soon.

And what does normalcy even look like in a COVID 2.0 world, anyway? What are the continuing safety measures businesses, hospitals and schools need to do to keep people safe now and into the future? John Shanahan, President and CEO of Ionogen, and Dr. Jack Lacey, retired CMO of the University of Tennessee’s Medical Center, spoke about the situation and how air sanitation can help keep spaces COVID-free.

New COVID variants are a reminder that the battle against the virus will be a lengthy one, and people need every weapon they can to fight it.

“COVID 1, COVID 2, what makes this virus unique is its ability to hang in the air,” Shanahan said. “We now know we have to take a responsible approach to cleaning the air.”

The bottom line is, even if everything else about an indoor space is clean and sanitized, if the air inside isn’t, COVID can travel and spread.

“COVID-19 most commonly spreads through close human contact and, specifically, through breathing and respiratory droplets,” Dr. Lacey said. “We know that the larger droplets can fall out of the air within the six feet we’re told to distance ourselves, but the much smaller droplets and viral particles can hang in the air for minutes to hours.”

Ionogen’s ionpure line of safe, non-hazardous sanitation products can help fight the coronavirus in the air and on surfaces to make spaces safer for people in facilities of all industries and settings.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The healthcare industry faces significant consequences when delayed decision-making occurs. Prompt and efficient action is crucial to prevent adverse impacts on patient care and operational efficiency. Addressing this issue requires a commitment to more agile and informed decision processes.

  • 01Delayed decision-making in healthcare can lead to negative impacts on patient care and operational efficiency.
  • 02Healthcare organizations are encouraged to adopt agile decision-making processes to improve effectiveness.
  • 03Implementing informed and prompt decision-making strategies can mitigate the risks of inefficiencies and poor patient outcomes.

Aug 17, 2026

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

The Centers for Medicare & Medicaid Services (CMS) launched its tech-enabled chronic care pilot program, known as the ACCESS pilot. Despite its initiation, a significant issue persists as patients struggle to find which healthcare providers are participating in the program. Meanwhile, the FDA has authorized 115 AI-based medical devices in 2021.

  • 01CMS has initiated the ACCESS pilot program to enhance chronic care management using technology.
  • 02Patients are facing challenges in identifying healthcare providers involved in the ACCESS pilot.
  • 03In 2021, the FDA authorized 115 AI-based medical devices.

Aug 17, 2026

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has appointed Guido Oelkers, the current CEO of Sobi, as its next chief executive. Oelkers is tasked with advancing BioNTech's oncology pipeline to achieve multiple approved products by 2030.

  • 01BioNTech has selected Guido Oelkers as its new CEO, effective soon.
  • 02Guido Oelkers aims to turn BioNTech's deep oncology pipeline into several approved products by 2030.

Aug 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512